



## Publication summary of AOSpine Knowledge Forum Spinal Cord Injury—Efficacy and safety of Riluzole in acute spinal cord injury study (RISCIS)

To access abstract or full text, click on PubMed link after reference.

### Peer-reviewed Journal Articles

1. Fehlings MG, Nakashima H, Nagoshi N, Chow DS, Grossman RG, Kopjar B. *Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial.* Spinal Cord 54(1): 8-15, 2016.

[PubMed](#)

2. Nagoshi N, Nakashima H, Fehlings MG. *Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.* Molecules 20(5): 7775-7789, 2015.

[PubMed](#)

3. Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, Shaffrey CI, Harkema SJ, Guest JD, Tator CH, Burau KD, Johnson MW, Grossman RG. *Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.* J Neurosurg Spine 17(1 Suppl): 151-156, 2012.

[PubMed](#)

4. Tator CH, Hashimoto R, Raich A, Norvell D, Fehlings MG, Harrop JS, Guest J, Aarabi B, Grossman RG. *Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury.* J Neurosurg Spine 17(1 Suppl): 157-229, 2012.

[PubMed](#)

### Conference Proceedings

#### Podium Presentations

1. **Fehlings MG**, Kopjar B. *Efficacy and Safety of Riluzole in Acute Spinal Cord Injury (SCI) Rationale and Design of AOSpine Phase III Multi-center Double Blinded Randomized Controlled Trial (RISCIS).* NASS 2017, Orlando, FL, USA, Oct 25-28, 2017.

2. **Fehlings M**, Nakashima H, Nagoshi N, Diana S, Chow L, Grossman RG, Kopjar B. *Timing of decompression in patients with acute spinal cord injury: a systematic review.* Global Spine Congress 2016, Dubai, UAE, April 13-16, 2016.

3. Jefferson Wilson, Lindsay Tetreault, Brian K Kwon, Paul M Arnold, Thomas Mroz, Chris Shaffrey, Jens Chapman, Steve Casha, Andrea Skelly, Holmer H, Erika Brodt, **Fehlings M**. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. Global Spine Congress 2016, Dubai, UAE, April 13-16, 2016.
4. **Fehlings M**, Wilson J, Arnold P, Skelly A, Chapman J, Tetreault L, Aarabi B, Harrop J. *A clinical guideline for the timing of surgical decompression in the treatment of acute traumatic spinal cord injury*. International Neurotrauma Society (INTS) meeting, Cape Town, South Africa, February 1-4, 2016.
5. **Fehlings M**, Wilson J, Kwon B, Kurpad S, Harrop J, Shamji M, Middleton J. *A clinical guideline for the use of high-dose Methylprednisolone in the treatment of acute traumatic spinal cord injury*. International Neurotrauma Society (INTS) meeting, Cape Town, South Africa, February 1-4, 2016.
6. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. 22nd International Meeting on Advanced Spine Techniques (IMAST), Kuala Lumpur, Malaysia, July 8-11, 2015.
7. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. ASIA/ISCOs Joint Scientific Meeting [American Spinal Injuria Association and International Spinal Cord Society], Montreal, Canada, May 14-16, 2015.
8. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. AO ONE Conference, Las Vegas, NV, USA, February 5-7, 2015.
9. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. North American Spine Society (NASS) 29th Annual Meeting, San Francisco, CA, USA, November 12-15, 2014.
10. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. Congress of Neurological Surgeons (CNS) Annual Meeting, Boston, MA, USA, October 18-22, 2014.
11. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. 21st International Meeting on Advanced Spine Techniques (IMAST), Valencia, Spain, July 16-19, 2014. **\*Winner of Whitecloud Award for Best Clinical Paper\***
12. **Fehlings MF**, Kopjar B, Grossman R. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. 20th International Meeting on Advanced Spine Techniques (IMAST), Vancouver, Canada, July 10-13, 2013.

### **Poster Presentations**

1. Fehlings M, Kopjar B, Grossman R. *Efficacy and Safety of Riluzole in Acute Spinal Cord Injury. Rationale and Design of AOSpine Phase III Multi-center Double Blinded Randomized Controlled Trial*. Praxis 2016, Vancouver, Canada, April 25-27, 2016.
2. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. North American Spine Society (NASS) 30th Annual Meeting, Chicago, IL, USA, October 14-17, 2015.

3. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. Congress of Neurological Surgeons (CNS) Annual Meeting, New Orleans, LA, USA, September 27-30, 2015.
4. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. Global Spine Congress 2015 Buenos Aires, Argentina, May 20-23, 2015.
5. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. 83rd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, Washington DC, USA, May 2-6, 2015.
6. **Fehlings MF**, Kopjar B, Grossman R, Wilson J. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. 31st Annual Meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, Phoenix, AZ, USA, March 4-7, 2015.
7. **Fehlings MF**, Kopjar B, Grossman R. *Efficacy and safety of Riluzole in acute spinal cord injury (SCI). Rationale and design of AOSpine phase III multi-center double-blinded randomized controlled trial (RISCIS)*. 82nd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, San Francisco, CA, USA, April 5-9, 2014.
8. **Fehlings MF**, Grossman R, Wilson J, Frankowski R, Kopjar B, Burau K, Chow D, Tator C, Teng A, Toups E, Harrop J, Aarabi B, Shaffrey C, Johns M. *The clinical translation of Riluzole for the treatment of traumatic spinal cord injury: design of a phase II/III trial*. 63rd Annual Meeting of the Congress of Neurological Surgeons (CNS), San Francisco, CA, USA, October 19-23, 2013.